Physician profile
Rachel Bernstein
NPI 1063947372
$4,348.75
in general payments reported to CMS, 2019-2025
24 companies · $1,685 in 2025
The $1,685 reported for 2025 was more than what 94% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $72.09 · 2022: $952 · 2023: $526 · 2024: $1,114 · 2025: $1,685.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,325.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,324.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $2,279.75 | 2022-2025 | Slynd, Tyblume, Nuvessa |
| Abbvie INC. | $453.13 | 2022-2025 | Ubrelvy, Lo Loestrin Fe, Qulipta |
| Mayne Pharma Commercial LLC | $345.04 | 2021-2025 | |
| Sage Therapeutics, LLC | $203.96 | 2025 | Zurzuvae |
| Exact Sciences Corporation | $147.01 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $134.60 | 2022-2025 | Veozah |
| Sumitomo Pharma America, INC. | $117.00 | 2024-2025 | Myfembree |
| Coopersurgical, INC. | $93.75 | 2023-2025 | Paragard T 380a, Paragard T 380a |
| Urovant Sciences INC | $78.88 | 2022 | |
| Pfizer INC. | $75.23 | 2022-2025 | |
| Glaxosmithkline, LLC. | $71.97 | 2023-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Myovant Sciences INC. | $47.49 | 2022 | |
| Agile Therapeutics, INC. | $37.77 | 2023 | Twirla |
| Merck Sharp & Dohme LLC | $36.03 | 2021-2022 | |
| Therapeuticsmd, INC. | $35.22 | 2021-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $30.03 | 2022 | |
| Conmed Corporation | $29.70 | 2025 | Airseal |
| Supernus Pharmaceuticals, INC. | $23.41 | 2025 | Qelbree |
| Lilly USA, LLC | $22.35 | 2025 | Zepbound |
| Organon LLC | $20.31 | 2024 | |
| Aspira Women'S Health INC | $19.96 | 2025 | Ova1 |
| Bayer Healthcare Pharmaceuticals INC. | $16.91 | 2022 | |
| Millicent US INC | $15.94 | 2025 | Intrarosa, Femlyv |
| Monaghan Medical Corporation | $13.31 | 2023 | Aerochamber |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Bernstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.